Three Decades of Research on the Development of Ibogaine Treatment of Substance Use Disorders: A Scientometric Analysis.

IF 2.1 4区 医学 Q2 PSYCHOLOGY, CLINICAL
Journal of psychoactive drugs Pub Date : 2024-11-01 Epub Date: 2023-11-06 DOI:10.1080/02791072.2023.2276230
Maria Helha Fernandes-Nascimento, André Brooking Negrão, Karine Viana-Ferreira, Bruno Daniel Rasmussen Chaves, Yuan-Pang Wang
{"title":"Three Decades of Research on the Development of Ibogaine Treatment of Substance Use Disorders: A Scientometric Analysis.","authors":"Maria Helha Fernandes-Nascimento, André Brooking Negrão, Karine Viana-Ferreira, Bruno Daniel Rasmussen Chaves, Yuan-Pang Wang","doi":"10.1080/02791072.2023.2276230","DOIUrl":null,"url":null,"abstract":"<p><p>Ibogaine is a natural psychoactive drug that has been investigated for its potential role in the treatment of substance use disorders since the mid-1960s. To evaluate the interest in ibogaine's use as a therapeutic agent, we performed a scientometric analysis covering the last three decades (1993-2002, 2003-2012, and 2013-2022). A complementary analysis was performed to select and describe published clinical trials and meta-analyses. A total of 1523 references were found. Linear growth of publications in the first and third decades were identified, and the average number of publications from 1993 to 2002 was lower than that in the other two decades. Researchers from five continents were identified. Globally, academic research centers in the United States and Canada were the most productive. Cocaine, tobacco, morphine, and alcohol prevailed as major keywords in the first two decades and opioids and psychedelics were included in the third decade. A few key authors were the most co-referenced. One preclinical meta-analysis and no meta-analysis in humans were found. Research trends for ibogaine are widespread, growing, and consonant with current attentiveness in drug abuse. Our findings support the pressing need for rigorous clinical research on ibogaine to evaluate its efficacy and safety.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"670-680"},"PeriodicalIF":2.1000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of psychoactive drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/02791072.2023.2276230","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}
引用次数: 0

Abstract

Ibogaine is a natural psychoactive drug that has been investigated for its potential role in the treatment of substance use disorders since the mid-1960s. To evaluate the interest in ibogaine's use as a therapeutic agent, we performed a scientometric analysis covering the last three decades (1993-2002, 2003-2012, and 2013-2022). A complementary analysis was performed to select and describe published clinical trials and meta-analyses. A total of 1523 references were found. Linear growth of publications in the first and third decades were identified, and the average number of publications from 1993 to 2002 was lower than that in the other two decades. Researchers from five continents were identified. Globally, academic research centers in the United States and Canada were the most productive. Cocaine, tobacco, morphine, and alcohol prevailed as major keywords in the first two decades and opioids and psychedelics were included in the third decade. A few key authors were the most co-referenced. One preclinical meta-analysis and no meta-analysis in humans were found. Research trends for ibogaine are widespread, growing, and consonant with current attentiveness in drug abuse. Our findings support the pressing need for rigorous clinical research on ibogaine to evaluate its efficacy and safety.

Ibogaine治疗药物使用障碍的三十年研究进展:科学分析。
Ibogaine是一种天然的精神活性药物,自20世纪60年代中期以来,人们一直在研究其在治疗药物使用障碍中的潜在作用。为了评估人们对伊波加因作为治疗剂的兴趣,我们对过去三十年(1993-2002年、2003-2012年和2013-2022年)进行了科学计量分析。进行了补充分析,以选择和描述已发表的临床试验和荟萃分析。共发现1523篇参考文献。确定了第一和第三十年出版物的线性增长,1993年至2002年的平均出版物数量低于其他二十年。来自五大洲的研究人员被确认身份。在全球范围内,美国和加拿大的学术研究中心的生产力最高。可卡因、烟草、吗啡和酒精在前二十年成为主要关键词,阿片类药物和迷幻药在第三个十年被纳入。一些主要作者被引用最多。一项临床前荟萃分析未在人类中发现。伊博加因的研究趋势是广泛的、不断增长的,并与当前对药物滥用的关注相一致。我们的研究结果支持迫切需要对伊博gaine进行严格的临床研究,以评估其疗效和安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.30
自引率
7.10%
发文量
62
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信